查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371952

2030 年超免疫球蛋白市场预测：按类型、最终用户和地区分類的全球分析

Hyperimmune Globulins Market Forecasts to 2030 - Global Analysis By Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Rho Immunoglobulins, Tetanus Immunoglobulins and Other Types), By End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球超免疫球蛋白市场规模为 20.1 亿美元，预计 2030 年将达到 36.9 亿美元。

超免疫球蛋白是从个体血浆中获得的特殊抗体製剂，具有针对特定病原体或抗原的高浓度抗体。这些抗体是从罹患特定疾病或接种过疫苗的捐赠者那里获得的，从而导致免疫系统产生强大的抗体反应。然后对超免疫球蛋白进行加工、精製和浓缩，以含有高水平的特异性抗体。这些製剂用于被动免疫，提供特定感染疾病的即时定向免疫。

各种感染疾病的流行

感染疾病仍然是全球面临的重大健康挑战，对有针对性的有效治疗方法的需求持续增长。超免疫球蛋白含有高浓度的抗体，可以对抗特定的病原体，有助于预防和治疗此类疾病。从肝炎到狂犬病感染疾病的罹患率不断增加，促使医疗保健系统投资于超免疫球蛋白产品。随着世界面临已知和新出现的感染疾病的威胁，市场份额不断增加，对抗这些疾病的新治疗方法不断增加，对超免疫球蛋白的需求仍然强劲，预计感染疾病发展将进一步加强。

捐赠者数量有限

超免疫球蛋白来自对某些病原体具有特异性抗体的个体。寻找足够数量的具有必要抗体的捐赠者是一个困难且集中资源的过程。这种限制使得难以扩大生产规模以满足对患病球蛋白的需求，特别是对于低流行性疾病和新出现的感染疾病威胁。此外，确保合格捐助者的持续和永续供应对于维持产品品质和功效至关重要。由于这种限制，超免疫球蛋白市场需要创新方法，例如人工抗体的开发以及更有效的捐赠者招募和收集策略，以克服捐赠者可用性的限制。

医疗保健专业人员的意识不断增强

随着医疗保健专业人员越来越了解超免疫球蛋白对特定感染疾病和病理的治疗效果，他们更有可能向患者推荐和给药这些专门的免疫球蛋白製剂。意识的提高可以促进早期诊断和治疗，从而改善患者的治疗效果。此外，资讯的医疗保健专业人员可以为扩大超免疫球蛋白针对已发现和新出现的感染疾病的研发和临床应用做出贡献。这将促进製药公司和医疗保健提供者之间的合作，最终促进超免疫球蛋白疗法的成长和可及性，同时改善患者照护和公共卫生结果。

保存期限有限

超免疫球蛋白产品的保质期通常相对较短，这可能会对储存、运输和分销带来物流挑战。在整个供应链中维持所需的温度和储存条件可能非常复杂且成本高昂。这种限制可能会导致产品浪费和经济损失，尤其是在指定期限内无法满足需求的情况下。此外，有效的库存管理对于防止过期和产品短缺也是必要的。减轻这项威胁需要储存技术的创新、延长产品的保质期和改进的分配系统，以确保超免疫球蛋白及时有效地到达患者手中。

COVID-19 的影响：

COVID-19 大流行加速了远距医疗的采用，并增加了对家庭超免疫球蛋白的需求。随着越来越多的人避开医疗机构，这些设备可以帮助人们在家中监测血压并帮助管理慢性病。远端健康咨询和远端监测已变得至关重要，数位和智慧型手机整合监测仪也普及越来越普遍。此次疫情凸显了自我照护和早期发现的重要性，推动了这段时期血压监测技术的创新和便利性。

医院和诊所预计将在预测期内成为最大的细分市场

医院和诊所在超免疫球蛋白市场中非常重要，它们是需要这些专门免疫球蛋白疗法的患者的主要护理和给药中心。这些医疗机构是超免疫球蛋白产品的分销和使用的中心，也是某些感染疾病的诊断、治疗和预防的中心。医院和诊所负责诊断需要超免疫球蛋白的疾病、实施治疗和管理病患照护。这些医院和诊所也是提高人们对超免疫球蛋白益处的认识的重要倡导者，并且通常负责采购和储存这些产品。超免疫球蛋白市场的成功和成长与医院和诊所在患者照护和公共卫生方面的参与和积极作用密切相关。

在预测期内，狂犬病免疫球蛋白领域预计将具有最高的年复合成长率

由于狂犬病预防意识的提高、某些地区狂犬病发病率的上升以及生产技术的改进，预计狂犬病免疫球蛋白领域在预测期内将出现显着增长。各国政府和卫生保健组织已启动狂犬病控制计画来解决这个公共卫生问题。此外，正在进行的研究和开发旨在提高狂犬病免疫球蛋白的效率和价格。狂犬病免疫球蛋白在狂犬病防治中发挥的重要作用，保证了超免疫球蛋白市场将持续成长。

比例最高的地区：

北美超免疫球蛋白市场预计近年来将经历强劲成长。这种快速增长是由于人们对被动免疫的认识增强，特别是在高危险群中。感染疾病罹患率的增加以及对快速起效的标靶免疫的需求正在推动需求。此外，医疗机构、研究机构和製药公司之间的策略联盟正在加速研发。北美凭藉其发达的医疗基础设施、严格的法律规范和不断增长的医疗支出，可能会继续引领超免疫球蛋白市场的成长。

复合年复合成长率最高的地区：

预计北美在预测期内将出现良好的成长。超免疫球蛋白在亚太地区的医疗保健中发挥重要作用。这些专门的抗体製剂对于应对和预防这个多样化和人口稠密地区流行的各种感染疾病至关重要。乙型肝炎、狂犬病和破伤风等疾病是主要的公共卫生问题。此外，亚太地区广阔的区域形势和人口多样性凸显了这些准备工作在保护公众健康和减轻感染疾病影响方面的重要性，而该地区的医疗保健已成为这种情况下的一个重要因素。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球超免疫球蛋白市场：按类型

  • 乙型肝炎免疫球蛋白
  • 狂犬病免疫球蛋白
  • Rho(D) 免疫球蛋白
  • 破伤风免疫球蛋白
  • 其他类型

第6章全球超免疫球蛋白市场：依最终用户分类

  • 医院和诊所
  • 血库和捐赠中心
  • 政府机关
  • 家庭保健
  • 製药公司
  • 其他最终用户

第7章全球超免疫球蛋白市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第8章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第9章公司简介

  • ADMA Biologics
  • Biotest
  • China National Biotec Group Company Limited（CNBG）
  • CSL Behring
  • Emergent（Cangene）
  • Grifols
  • Hualan Bio
  • Kamada
  • Kedrion
  • Shanghai Raas Blood Products Co. Ltd
  • Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.
Product Code: SMRC24009

According to Stratistics MRC, the Global Hyperimmune Globulins Market is accounted for $2.01 billion in 2023 and is expected to reach $3.69 billion by 2030 growing at a CAGR of 9% during the forecast period. Hyperimmune globulins are specialized preparations of antibodies that are derived from the blood plasma of individuals who have a high concentration of antibodies against a specific pathogen or antigen. These antibodies are collected from donors who have been exposed to or vaccinated against a particular disease, resulting in their immune system producing a robust antibody response. Hyperimmune globulins are then processed, purified, and concentrated to contain high levels of specific antibodies. These preparations are used for passive immunization, providing immediate and targeted immunity against particular infections.

Market Dynamics:

Driver:

The prevalence of various infectious diseases

The infectious diseases continuing to pose significant global health challenges, there is an ever-growing demand for targeted and effective therapies. Hyperimmune globulins, containing high concentrations of specific pathogen-fighting antibodies, are instrumental in preventing and treating such diseases. The increasing incidence of infectious diseases, ranging from hepatitis to rabies, prompts healthcare systems to invest in hyperimmune globulin products, as they offer critical support for patients, especially in cases where conventional treatments may be limited. As the world faces both known and emerging infectious threats, the demand for hyperimmune globulins is expected to remain robust, further bolstering their market presence and the development of new therapies to combat these diseases.

Restraint:

Limited availability of donors

Hyperimmune globulins are derived from individuals who possess specific antibodies against a particular pathogen. Finding an adequate number of donors with the necessary antibodies can be a challenging and resource-intensive process. This limitation can result in difficulties in scaling up production to meet the demand for hyperimmune globulins, particularly for diseases with a low prevalence or for emerging infectious threats. Moreover, ensuring a consistent and sustainable supply of qualified donors is essential for maintaining product quality and efficacy. This constraint necessitates innovative approaches, such as the development of artificial antibodies or more efficient donor recruitment and collection strategies, to overcome the limited availability of donors in the hyperimmune globulins market.

Opportunity:

Growing awareness among healthcare professionals

As healthcare providers become more informed about the therapeutic benefits of hyperimmune globulins in addressing specific infectious diseases and conditions, they are more likely to recommend and administer these specialized immunoglobulin products to their patients. Enhanced awareness can lead to earlier diagnosis and treatment, resulting in better patient outcomes. Additionally, informed healthcare professionals can contribute to increased research, development, and clinical utilization of hyperimmune globulins for both existing and emerging infectious diseases. This can foster collaboration between pharmaceutical companies and healthcare practitioners, ultimately driving the growth and accessibility of hyperimmune globulin therapies, while improving patient care and public health outcomes.

Threat:

Limited shelf life

Hyperimmune globulin products typically have a relatively short shelf life, which can lead to logistical challenges in terms of storage, transportation, and distribution. Maintaining the required temperature and storage conditions throughout the supply chain can be complex and costly. This constraint can result in product wastage, especially if the demand is not met within the specified timeframe, leading to financial losses. It also necessitates efficient inventory management to prevent expiration and product shortages. To mitigate this threat, there is a need for innovations in storage and preservation techniques, extended shelf life products, and improved distribution systems to ensure that hyperimmune globulins reach patients in a timely and effective manner.

COVID-19 Impact:

The COVID-19 pandemic has accelerated the adoption of remote healthcare, increasing the demand for home Hyperimmune Globulins. With more people avoiding healthcare facilities, these devices allow individuals to monitor their blood pressure from home, aiding in the management of chronic conditions. Telehealth consultations and remote monitoring have become essential, making digital and smartphone-integrated monitors more popular. The pandemic has underscored the importance of self-care and early detection, driving innovation and convenience in blood pressure monitoring technology during this period.

The hospitals & clinics segment is expected to be the largest during the forecast period

Hospitals and clinics are significant in the hyperimmune globulins market as primary points of care and administration for patients in need of these specialized immunoglobulin therapies. These healthcare facilities are central in the distribution and utilization of hyperimmune globulin products, serving as hubs for diagnosis, treatment, and preventive measures against specific infectious diseases. Hospitals and clinics are responsible for diagnosing conditions that require hyperimmune globulins, administering treatments, and managing patient care. They also serve as key advocates in raising awareness about the benefits of hyperimmune globulins and, in many cases, are responsible for procuring and stocking these products. The success and growth of the hyperimmune globulins market are closely tied to the engagement and proactive role of hospitals and clinics in patient care and public health.

The rabies immunoglobulins segment is expected to have the highest CAGR during the forecast period

The rabies immunoglobulins segment is expected to witness significant growth over the forecast period driven by increasing awareness of rabies prevention, a rising incidence of rabies in certain regions, and improved production techniques. Governments and healthcare organizations have initiated rabies control programs to address this public health concern. Moreover, ongoing research and development efforts aim to enhance the efficiency and affordability of rabies immunoglobulins. The critical role that rabies immunoglobulins play in preventing and treating rabies ensures their continued growth within the broader hyperimmune globulins market.

Region with largest share:

The market for Hyperimmune Globulins in North America is expected to witness robust growth in recent years. This surge can be attributed to rising awareness about passive immunization, especially in high-risk populations. Increasing incidence of infectious diseases and the need for immediate, targeted immunity have driven demand. Additionally, strategic collaborations between healthcare institutions, research organizations, and pharmaceutical companies have accelerated research and development efforts. With a well-established healthcare infrastructure, stringent regulatory framework, and growing healthcare expenditure, North America is poised to continue leading in hyperimmune globulins market growth.

Region with highest CAGR:

During the forecast period, North America is anticipated to witness lucrative growth. Hyperimmune globulins play a critical role in healthcare throughout the Asia-Pacific region. These specialized antibody preparations are vital for addressing and preventing a range of infectious diseases prevalent in this diverse and populous area. Diseases like hepatitis B, rabies, and tetanus are significant public health concerns. Moreover, Asia-Pacific's vast geographic and demographic diversity underscores the importance of these preparations in safeguarding public health and mitigating the impact of infectious diseases, making them an essential component of the healthcare landscape in the region.

Key players in the market:

Some of the key players in Hyperimmune Globulins market include: ADMA Biologics, Biotest, China National Biotec Group Company Limited (CNBG), CSL Behring, Emergent (Cangene), Grifols, Hualan Bio, Kamada, Kedrion, Shanghai Raas Blood Products Co. Ltd and Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

Key Developments:

In July 2023, Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, has announced that China's National Institutes for Food and Drug Control (NIFDC) has approved BPL's human Albumin product for release to the Chinese market. In 2022, Kedrion joined forces with BPL, a UK-based company with over 60 years of experience in the supply of high-quality plasma-derived medicines for the treatment of rare diseases.

In March 2023, Grifols entered into a collaboration and licensing agreement with Selagine to develop immunoglobulin (Ig) eye drops to treat dry eye disease. Under the terms of the agreement, Grifols will have worldwide exclusive commercial rights to Selagine's treatment once it receives the regulatory authorization, expected in early 2029.

In January 2022, LFB and Kedrion signed an industrial cooperation agreement to supply immunoglobulins to meet patient demand in France. Two leading European pharmaceutical companies, LFB and Kedrion, are joining forces in an industrial cooperation agreement to increase the availability of immunoglobulin, a plasma-derived medicine, for patients in France.

Types Covered:

  • Hepatitis B Immunoglobulins
  • Rabies Immunoglobulins
  • Rho(D) Immunoglobulins
  • Tetanus Immunoglobulins
  • Other Types

End Users Covered:

  • Hospitals & Clinics
  • Blood Banks and Donation Centers
  • Government Institutions
  • Home Healthcare
  • Pharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hyperimmune Globulins Market, By Type

  • 5.1 Introduction
  • 5.2 Hepatitis B Immunoglobulins
  • 5.3 Rabies Immunoglobulins
  • 5.4 Rho(D) Immunoglobulins
  • 5.5 Tetanus Immunoglobulins
  • 5.6 Other Types

6 Global Hyperimmune Globulins Market, By End User

  • 6.1 Introduction
  • 6.2 Hospitals & Clinics
  • 6.3 Blood Banks and Donation Centers
  • 6.4 Government Institutions
  • 6.5 Home Healthcare
  • 6.6 Pharmaceutical Companies
  • 6.7 Other End Users

7 Global Hyperimmune Globulins Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 ADMA Biologics
  • 9.2 Biotest
  • 9.3 China National Biotec Group Company Limited (CNBG)
  • 9.4 CSL Behring
  • 9.5 Emergent (Cangene)
  • 9.6 Grifols
  • 9.7 Hualan Bio
  • 9.8 Kamada
  • 9.9 Kedrion
  • 9.10 Shanghai Raas Blood Products Co. Ltd
  • 9.11 Sichuan Yuanda Shuyang Pharmaceutical Co.,Ltd.

List of Tables

  • Table 1 Global Hyperimmune Globulins Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 4 Global Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 5 Global Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 6 Global Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 7 Global Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 9 Global Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 10 Global Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 11 Global Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 12 Global Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 13 Global Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 14 Global Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 15 North America Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 16 North America Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 17 North America Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 18 North America Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 19 North America Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 20 North America Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 21 North America Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 22 North America Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 North America Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 24 North America Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 25 North America Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 26 North America Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 27 North America Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 28 North America Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 29 Europe Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 30 Europe Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 31 Europe Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 32 Europe Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 33 Europe Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 34 Europe Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 35 Europe Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 36 Europe Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 Europe Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 38 Europe Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 39 Europe Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 40 Europe Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 41 Europe Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 42 Europe Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Asia Pacific Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Asia Pacific Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 45 Asia Pacific Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 46 Asia Pacific Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 47 Asia Pacific Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 48 Asia Pacific Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 49 Asia Pacific Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 50 Asia Pacific Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 51 Asia Pacific Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 52 Asia Pacific Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 53 Asia Pacific Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 54 Asia Pacific Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 55 Asia Pacific Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 56 Asia Pacific Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 57 South America Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 58 South America Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 59 South America Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 60 South America Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 61 South America Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 62 South America Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 63 South America Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 64 South America Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 65 South America Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 66 South America Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 67 South America Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 68 South America Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 69 South America Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 70 South America Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 71 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Country (2021-2030) ($MN)
  • Table 72 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Type (2021-2030) ($MN)
  • Table 73 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Hepatitis B Immunoglobulins (2021-2030) ($MN)
  • Table 74 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Rabies Immunoglobulins (2021-2030) ($MN)
  • Table 75 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Rho(D) Immunoglobulins (2021-2030) ($MN)
  • Table 76 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Tetanus Immunoglobulins (2021-2030) ($MN)
  • Table 77 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 78 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By End User (2021-2030) ($MN)
  • Table 79 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 80 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Blood Banks and Donation Centers (2021-2030) ($MN)
  • Table 81 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Government Institutions (2021-2030) ($MN)
  • Table 82 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Home Healthcare (2021-2030) ($MN)
  • Table 83 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Pharmaceutical Companies (2021-2030) ($MN)
  • Table 84 Rest of Middle East & Africa Hyperimmune Globulins Market Outlook, By Other End Users (2021-2030) ($MN)